MedTrace Logo

Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

NCT04419441 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2020-09-16

No results posted yet for this study

Summary

This is an observational retrospective study to investigate the efficacy and safety of the treatment with an immune checkpoint inhibitor (nivolumab or pembrolizumab) in combination with radiotherapy in patients with relapsed/refractory classical Hodgkin lymphoma.

Conditions

Interventions

DRUG

Immune checkpoint inhibitor

concomitant administration of radiotherapy and immune checkpoint inhibitor

Sponsors & Collaborators

  • Ospedale Maggiore Di Trieste

    lead OTHER

Principal Investigators

  • Francesco Zaja, Professor · SC Ematologia Ospedale Maggiore Trieste

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-24
Primary Completion
2020-09-30
Completion
2020-09-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04419441 on ClinicalTrials.gov